Interview
Johann Hari: They’re Lying To You About The Side Effects Of Ozempic!
- Market adoption is predicted to rise significantly, with 47% of Americans expressing willingness to take the drugs, potentially leading to 50% of the population usage within a few years absent government intervention.
- The market value is forecast to reach $200 billion by the end of this decade, driven by new drug releases like GGG expected next year which may cause an average 24.2% weight loss, while next-generation drugs could yield 24% average weight loss.
- Long-term efficacy risks include a 70% weight regain within one year of stopping medication, the development of tolerance requiring higher doses, and the potential for a reset biological set point or slower metabolism post-withdrawal.
- Specific drug outcomes include Munjaro causing a 21% average weight loss, a shift to oral semaglutide formulations by 2032, and a drop in production costs to $40 monthly after the Ozempic patent expires in 2032.
- Medical risks identified include a 20-30% loss of lean muscle mass, a ninefold increase in pancreatitis risk, a 50-75% increased risk of thyroid cancer, and potential birth defects based on animal studies.
- Mental health and behavioral side effects encompass a 17% rate of inpatient psychiatric treatment for bariatric surgery patients, a nearly fourfold increase in suicide rates post-surgery, a one-in-ten risk of addiction transfer to substances or behaviors, and reports of emotional dulling or "Zempek face."
- Societal and economic shifts anticipate decreased stock values for orthopedic companies, jet fuel costs, and food manufacturers like Nestle and Krispy Kreme, while airlines may see reduced fuel spending due to a thinner population.
- Historical precedents are drawn from smoking rates falling from over 50% in 1987 to 12% in the future and the 1970 statistic where 8% of US prescriptions were amphetamine-based, alongside 1990s fen-phen usage of 18 million prescriptions.
- Future regulatory scenarios involve potential bans on children's drug access, restrictions on indoor smoking, and concerns regarding "mass drugging" if no regulations are implemented.
- Demographic risks highlight a 42% higher rate of anorexia and bulimia in teenage girls aged 13-16 and 32% higher rates for those aged 17-19 following March 2020, with fears of young women causing self-harm via eating disorders.
- Health benefits are projected for specific groups, including a 40% reduced all-cause mortality over seven years for surgery patients, a 20% reduction in heart attack or stroke risk for those with BMI over 27 taking drugs within five years, and a 56% to 92% reduction in mortality from heart attacks, cancer, and diabetes respectively within seven years for gastric band surgery recipients.
- Unknown risks include potential "unknown unknowns" regarding long-term effects on memory and processing similar to antipsychotic-Alzheimer's links, as well as the dampening of rewards for non-food activities like writing or reading.
- Patient experiences may range from feelings of guilt, shame, and isolation due to cultural stigma, to relief and empowerment, alongside concerns about the "trapped" nature of lifelong medication use and the loss of pleasure in eating.